Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Change in Receivables (2020 - 2025)

Bioventus' Change in Receivables history spans 6 years, with the latest figure at -$1.9 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 132.54% year-over-year to -$1.9 million; the TTM value through Dec 2025 reached $916000.0, down 91.41%, while the annual FY2025 figure was $916000.0, 91.41% down from the prior year.
  • Change in Receivables reached -$1.9 million in Q4 2025 per BVS's latest filing, down from -$1.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $25.6 million in Q3 2022 to a low of -$17.1 million in Q3 2024.
  • Average Change in Receivables over 5 years is $2.0 million, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Change in Receivables: skyrocketed 989.74% in 2024, then tumbled 559.86% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $6.9 million in 2021, then crashed by 30.0% to $4.8 million in 2022, then surged by 90.23% to $9.2 million in 2023, then crashed by 36.99% to $5.8 million in 2024, then crashed by 132.54% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Change in Receivables are -$1.9 million (Q4 2025), -$1.8 million (Q3 2025), and $13.6 million (Q2 2025).